




The relative strengths and weaknesses of Kalvista Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kalvista Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 131% points. The greatest weakness of Kalvista Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 360%, being 115% points above the market average of 245%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 193,647              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 11,576               |
| Liabilities, Non-Current                    | 7,211                |
| Other Assets                                | 8,055                |
| Other Compr. Net Income                     | -2,429               |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 14,274               |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 2,178                |
| Research and Development                    | 70,167               |
| Selling, General and Administrative Expense | 26,446               |

| Output Variable              | Value in<br>1000 USD |
|------------------------------|----------------------|
| Assets                       | 203,880              |
| Liabilities                  | 18,787               |
| Expenses                     | 96,613               |
| Revenues                     | 0                    |
| Stockholders Equity          | 185,093              |
| Net Income                   | -82,339              |
| Comprehensive Net Income     | -83,554              |
| BaseVar                      | 167,992              |
| ECR before Limited Liability | 287%                 |
| Economic Capital Ratio       | 360%                 |